An independent resource on ibogaine and depression research.
Koru Vale / Services
Guides, comparisons, and research summaries for adults and families trying to make sense of ibogaine treatment for depression without overstating what the evidence can support.
Purpose
Koru Vale offers plain-language information services for people considering how ibogaine is discussed in relation to depression. The aim is not to direct care or recommend a treatment. It is to make the questions easier to see: what is known, what remains uncertain, where risks may sit, and which claims deserve closer scrutiny.
Our starting point is the broader ibogaine and depression resource, built for adults exploring treatment-resistant depression information as well as families, advocates, and policy-minded visitors. Each guide keeps investigational status in view and avoids presenting personal accounts or marketing language as clinical proof.
Ibogaine is a psychoactive alkaloid associated with the West African shrub Tabernanthe iboga. That botanical and cultural context does not settle questions about safety, effectiveness, legality, or suitability for depression; those questions require separate, careful attention.
How to use the material
These materials are designed to help readers distinguish an informational overview from medical guidance. Depression is a serious condition, and treatment decisions can involve urgent concerns, personal history, medications, and the need for qualified clinical care. The National Institute of Mental Health describes depression as a mood disorder that can affect how a person feels, thinks, and handles daily activities in its overview of depression.
For questions about how this resource approaches sources, limits, and independence, see Koru Vale’s stated purpose and methods. The work is organized to support informed reading, not to replace screening, diagnosis, emergency support, or medical advice.
“The useful question is not whether a claim sounds promising, but what evidence, safeguards, and unknowns sit behind it.”
Informational offerings
These are research and orientation tools. They are not clinical services, referrals, or treatment plans.
Plain-language explainers map basic terminology, common questions, and the limits of current discussion. A guide to what ibogaine does can help readers separate broad descriptions of the substance from claims about depression outcomes.
Comparison materials identify differences in setting, language, claims, and stated procedures without endorsing any provider. Readers examining descriptions of how ibogaine is administered can use that context to form more specific questions about oversight and risk.
Research summaries distinguish preliminary findings, study limitations, and unanswered questions. The research landscape is presented as evolving evidence, not a basis for predicting an individual result or making a treatment recommendation.
Safety materials make room for the serious concerns that marketing can minimize. The U.S. Food and Drug Administration explains that ibogaine use carries important safety risks, including potentially dangerous cardiac effects; this makes careful screening questions essential rather than optional.
Orientation notes help readers recognize that treatment environments and legal frameworks differ. Information about ibogaine centers in Mexico, along with a separate overview of ibogaine treatment facilities, is best read as background for due diligence rather than as a recommendation or verification of care quality.
FAQ collections address recurring questions about investigational use, regulations, and practical language. For example, discussion of ibogaine in the United States should be read alongside current official rules and the recognition that legal status does not establish safety or effectiveness for depression.
FAQ
No. Koru Vale is an independent information resource, not a clinic, medical provider, or licensed treatment center. The materials do not diagnose depression, determine eligibility, or provide medical direction.
No. A summary can describe study designs and findings, but it cannot turn an investigational area into an established treatment. Questions about evidence should remain connected to the safety considerations and limitations described throughout the resource.
It can help identify questions worth asking, including how claims are framed and what information is missing. It cannot validate a facility, assess an individual’s medical risk, or substitute for qualified professional advice.
The Koru Vale approach
Our mission is to help people understand the evolving evidence, risks, policy, and practical questions around investigational ibogaine use for depression. The goal is a steadier starting point for reading—not a promise about treatment.